Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

About multiple sclerosis Multiple sclerosis is a chronic ... Tolebrutinib represents Sanofi's commitment to developing innovative treatments that address the underlying causes of neurological ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Throughout the course of multiple sclerosis, gradually progressive neurologic ... full text of this article at NEJM.org. Supported by Sanofi. Disclosure forms provided by the authors are available ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive ...

Hoffman-LaRoche, Novartis, and Sanofi. Source Reference: Oh J, et al "Tolebrutinib versus teriflunomide in relapsing multiple sclerosis" N Engl J Med 2025; DOI: 10.1056/NEJMoa2415985.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.” Dr Fox is a paid advisor to Sanofi ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.” Dr Fox is a paid advisor to Sanofi ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...